Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Clovis Oncology Fell 7.1% in August

TheMotleyFool 
0 0 07.09.17
Why Clovis Oncology Fell 7.1% in AugustPhoto, wide shot, wide-angle lens, Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png
 
Why Clovis Oncology Fell 7.1% in August

Shares of Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech focused on cancer, fell more than 7% in August, according to data from S&P Global Market Intelligence. The decline was owed to the company sharing good and bad news with investors during in its second-quarter report.

Here's a review of the headline numbers from the company's second quarter:

Financial updates aside, Clovis also had several other highlights to share with investors:

Continue reading


Source: Fool.com

Bristol-Myers Squibb Stock

€56.07
-2.780%
A loss of -2.780% shows a downward development for Bristol-Myers Squibb.
The stock is one of the favorites of our community with 22 Buy predictions and 3 Sell predictions.
With a target price of 60 € there is a slightly positive potential of 7.01% for Bristol-Myers Squibb compared to the current price of 56.07 €.
Show more
Like: 0
BMY
Share

Comments

Not a member yet? Sign up for free!